It’s easy to fall into the trap of judging a company by the performance of its share price. For liver cancer treatment company Sirtex Medical, the stock hasn’t advanced since we commenced coverage in Sirtex enters remission on 8 Nov 10 (Speculative Buy – $5.90). Indeed, the decline from around $6.00 to less than $4.50 over the course of calendar 2011 was probably disheartening.
In an industry like this, progress takes time. But the undeniable fact is that Sirtex’s story has improved significantly over the past 18 months.
